Premium
Anti‐AQP4 and anti‐MOG optic neuropathies
Author(s) -
YuWaiMan Patrick
Publication year - 2019
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2019.8052
Subject(s) - neuromyelitis optica , myelin oligodendrocyte glycoprotein , medicine , optic nerve , multiple sclerosis , spinal cord , optic neuropathy , central nervous system , demyelinating disease , neuroscience , aquaporin 4 , pathology , optic neuritis , immunology , ophthalmology , experimental autoimmune encephalomyelitis , biology , psychiatry
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system (CNS) that preferentially targets the optic nerve and the spinal cord. Due to the significant risk of permanent visual and neurological impairment in NMO, rapid diagnosis and the prompt initiation of the most appropriate treatment are essential. Antibodies against the aquaporin‐4 (AQP4) water channel and myelin oligodendrocyte glycoprotein (MOG) have been identified in patients with NMO phenotypes. In this presentation, the clinical and neuropathological features of anti‐AQP4 and anti‐MOG optic neuropathies will be reviewed with a critical appraisal of current treatment options.